Exosens (LON:0EXO)
London · Delayed Price · Currency is GBP · Price in EUR | Market Cap | 2.49B +59.3% |
| Revenue (ttm) | 408.43M +25.2% |
| Net Income | 37.26M +95.6% |
| EPS | 0.73 +212.1% |
| Shares Out | n/a |
| PE Ratio | 66.85 |
| Forward PE | 27.73 |
| Dividend | 0.08 (0.13%) |
| Ex-Dividend Date | May 28, 2025 |
| Volume | 158,141 |
| Average Volume | 78,859 |
| Open | 65.20 |
| Previous Close | 65.00 |
| Day's Range | 65.20 - 65.20 |
| 52-Week Range | 33.90 - 72.00 |
| Beta | n/a |
| RSI | 56.67 |
| Earnings Date | Jul 28, 2026 |
About Exosens
Exosens, together with its subsidiaries, develops, manufactures, and sells electro-optical technologies in France, Europe, North America, Asia, and internationally. It operates in two segments, Amplification and Detection and Imaging. The company offers image intensifier tubes; cameras, sensors, modules and cores, and imaging systems and solutions, including UV missile warning solution, atmospheric sounder, and spectroradiometer; and detection and imaging products for ions and electrons, photons, and neutrons, as well as micro pore optics and c... [Read more]
Financial Performance
In 2025, Exosens's revenue was 468.19 million, an increase of 22.10% compared to the previous year's 383.44 million. Earnings were 42.72 million, an increase of 67.31%.
Financial numbers in EUR Financial StatementsNews
Exosens price target raised to EUR 72 from EUR 69 at Berenberg
Berenberg raised the firm’s price target on Exosens (EXOSF) to EUR 72 from EUR 69 and keeps a Buy rating on the shares.
Exosens price target raised to EUR 71 from EUR 60 at JPMorgan
JPMorgan analyst David Perry raised the firm’s price target on Exosens (EXOSF) to EUR 71 from EUR 60 and keeps an Overweight rating on the shares.
Exosens price target raised to EUR 55 from EUR 52 at Deutsche Bank
Deutsche Bank analyst Sriram Krishnan raised the firm’s price target on Exosens (EXOSF) to EUR 55 from EUR 52 and keeps a Hold rating on the shares. Published first on
Exosens price target raised to EUR 59.30 from EUR 37 at Citi
Citi raised the firm’s price target on Exosens (EXOSF) to EUR 59.30 from EUR 37 and keeps a Neutral rating on the shares.
Exosens price target raised to EUR 69 from EUR 57 at Berenberg
Berenberg analyst Amelie Dueckelmann-Dublany raised the firm’s price target on Exosens (EXOSF) to EUR 69 from EUR 57 and keeps a Buy rating on the shares.
Exosens FY25 Profit Climbs, Sees Growth Ahead; Stock Down
(RTTNews) - Exosens S.A (EXENS.PA, EXOSF), a French manufacturer of electro-optical technologies, reported Monday higher profit in fiscal 2025, benefited by growth in revenues.
Exosens Earnings Call Transcript: Q4 2025
Delivered record 2025 results with 22% revenue growth, 32.4% EBITDA margin, and strong cash flow. Upgraded 2026 guidance, continued capacity expansion, and strategic M&A support midterm ambition to reach EUR 1 billion revenue.
THEON completes the acquisition of a circa 9.8% stake in Exosens
PRESS RELEASE Bloomberg (THEON:NA) / Reuters (THEON.AS) 7 January 2026 – Theon International Plc (THEON) is pleased to announce the completion of the acquisition of a circa 9.8% stake in Exosens SA (E...
Exosens upgraded to Hold from Reduce at Kepler Cheuvreux
Kepler Cheuvreux analyst Aymeric Poulain upgraded Exosens (EXOSF) to Hold from Reduce with a EUR 47.20 price target
Exosens price target raised to EUR 60 from EUR 54 at JPMorgan
JPMorgan analyst David Perry raised the firm’s price target on Exosens (EXOSF) to EUR 60 from EUR 54 and keeps an Overweight rating on the shares.
Theon International To Acquire 9.8% Stake In Exosens For EUR 268.7 Mln
(RTTNews) - Theon International Plc announced that it has signed a definitive agreement with HLD Europe SCA, Invest Prince Henri SCA, and Invest Gamma Sarl—investment entities affiliated with Groupe H...
Exosens Earnings Call Transcript: Q2 2025
H1 2025 saw 20% revenue growth and 24% adjusted EBITDA growth, driven by strong defense demand, acquisitions, and margin expansion. Capacity investments and a robust backlog support positive guidance for 2025, with continued focus on R&D and selective M&A.
Exosens Earnings Call Transcript: Q4 2024
Revenue grew 35% to EUR 394 million in 2024, with EBITDA margin at 30.1% and net profit up 66%. Strong defense demand, capacity expansion, and successful M&A drove results. 2025 guidance anticipates continued double-digit growth and further margin improvement.